1.0
IAM hiring
Hiring an IAM Engineer in Pharma: Why Access Control Is Now a GxP Job
IAM engineer hiring is tougher in pharma than elsewhere, because a drug company treats access control as a regulatory duty as well as a security task. FDA rules require drug makers to limit their electronic record systems to authorized people. In 2026 the FDA cited shared logins and analysts with administrator rights in several warning letters.

1.1
The role
What an IAM engineer does in a pharma company
Between August and November 2026, Biogen, Genentech, Pfizer, Moderna and Boston Scientific all advertised identity roles, at base pay of up to $263,500. Below: what the role involves, what regulators now expect, the ads and pay on offer, and why good candidates are scarce.
Identity and access management (IAM) is the part of IT security that decides who can log in to which system, with which rights, and for how long. An IAM engineer puts those decisions into software, so they happen automatically and can be proven later.
In practice the work falls into four areas:
- Identity governance, often on SailPoint or Saviynt. Accounts are created when someone joins, changed when they move roles and removed when they leave. Managers confirm their team's access in regular reviews.
- Single sign-on and multi-factor authentication, usually on Microsoft Entra ID or Okta, so people log in once, securely, to hundreds of applications.
- Privileged access management (PAM), often on CyberArk, which locks down the administrator accounts that can change systems and data.
- Directory services, the Active Directory and Entra ID estate that everything else depends on.
The scale is easy to underestimate. In October 2026, PCI Pharma advertised for an engineer to own identity for more than 6,500 users across 16 global sites. The brief included "21 CFR Part 11 identity controls". Every one of those users needs the right access to the right systems on day one, and none of it on the day after they leave.
IAM is part of the wider security function covered in our guide to hiring cybersecurity talent for pharma and biotech. Day to day, it often works most closely with the IT support team that handles access requests.
Sources: PCI Pharma, Identity & Access Engineer III (October 2026).
1.2
The GxP link
Why access control is a regulatory issue in life sciences
In a bank, a shared login is a security weakness. In a drug company, it can make test results untrustworthy, because nobody can prove who produced them.
US rules have required access control for decades. FDA's rule on electronic records, 21 CFR Part 11, requires "limiting system access to authorized individuals" and authority checks so that only authorized people can sign or alter a record. The drug manufacturing rules, 21 CFR 211.68(b), require controls so that only authorized personnel can change production and control records.
Inspectors keep finding the gap. Three FDA warning letters from 2026 show what it looks like:
- Ava Inc., Willowbrook, Illinois (April 14, 2026). Analysts shared one username and password on chromatography equipment used to test drugs. They also held administrator rights that let them modify and delete data. Investigators found deleted test sequences in the recycle bin.
- Fareva Amboise, France (April 10, 2026). Staff were able to alter alarm limits, access settings and even the system clock with no restriction, and logging on to the network needed no user authentication.
- Curia New York, Rensselaer (September 18, 2026). An analyst used a colleague's credentials to run calibrations and sample testing, even though the company's own procedure banned it. FDA wrote that "the sharing of credentials constitutes a serious violation of data-integrity principles" and asked for an independent assessment of every computerized system, not only the ones it had seen.
Europe is moving the same way, in more detail. A draft revision of EU GMP Annex 11 went out for consultation in July 2025, issued jointly by the European Commission and PIC/S. For the first time, identity and access management gets its own section. It says shared accounts, apart from read-only ones, "constitute a violation of data integrity". Anyone logging in to a critical system from outside the company network should use multi-factor authentication. Managers should regularly confirm that their staff still need the access they hold, and people doing GMP work should not have administrator rights. As of late September 2026 the final text had not been published, but the direction is clear.
Put together, these documents make IAM part of the quality system. An IAM engineer in pharma is building controls that auditors and inspectors will test, and that the company's data integrity depends on. For the validation specialists who test those controls, see our article on GxP compliance and IT validation hiring.
Sources: FDA warning letter to Ava Inc. (April 14, 2026); ECA Academy, FDA warning letter to Fareva Amboise (August 2026); GMP News, FDA cites Curia New York (September 30, 2026); European Commission, draft Annex 11 consultation document (July 2025); Comeply, the draft Annex 11 and its timeline (September 30, 2026).
1.3
Job ads
Who is hiring IAM engineers in life sciences
Each ad in this table was live at some point from August to November 2026. Most of them name GxP, SOX or Part 11 alongside the identity tools, which is the clearest sign of how pharma's version of the job differs.
| Employer and role | Where | What the ad asks for |
|---|---|---|
| Biogen, Sr. IT Solution Architect, Access Automation | Cambridge, Massachusetts or Research Triangle Park, North Carolina | Enterprise identity governance on SailPoint Identity Security Cloud with ServiceNow as the front end, and solutions that meet GxP and SOX. Base $140,000 to $187,250 |
| Genentech (Roche), Principal Enterprise Identity Engineer | South San Francisco, California | Global identity strategy, zero-trust architecture and SailPoint at scale, with 5+ years in highly regulated environments. Base $114,900 to $263,500 |
| Pfizer, Senior Associate, Identity Governance Engineering | Location not stated in the listing we saw | Hands-on SailPoint engineering: custom connectors, joiner, mover and leaver workflows, role-based access, aligned to SOX, HIPAA and NIST |
| Moderna, Senior Privileged Access Management Engineer | Norwood, Massachusetts | Owning the CyberArk platform across cloud and on-premises systems, with experience in GxP environments among the preferred qualifications. Base $145,900 to $234,200 |
| Boston Scientific, Principal Identity Security Engineer (PAM) | Arden Hills, Minnesota | CyberArk leadership, just-in-time access and controls for non-human identities, including AI agents |
| Recursion, Staff Engineer, Identity & Access Management | Salt Lake City, Utah | Rebuilding the company's IAM strategy and designing identity controls that meet SOX and GxP |
| Sanofi, Identity Governance technical lead | Hyderabad, India | Saviynt workflows, segregation of duties and access certifications for a centralized access product, with GxP and SOX controls |
A few things stand out. Nearly every ad names a specific platform: SailPoint or Saviynt for governance, CyberArk for privileged access, and Microsoft Entra ID or Active Directory underneath. The regulated part of the job is written into the ads, not left to the quality team. Biogen, Recursion and Sanofi all ask the IAM hire to make their solutions meet GxP and SOX requirements. And identity now covers machines as well as people. Boston Scientific's ad includes service accounts, application identities and AI agents.
Demand shows up in broader counts too. In our Pharma IT Hiring Index for November 2026, "identity and access management" appeared in more than 16 US Indeed ads alongside the word pharmaceutical. The same index found pharma employers increasingly expecting the people who run networks and cloud platforms to secure them too. The seven ads are a sample we reviewed, not a census.
Sources: Biogen (updated October 14, 2026); Genentech (posted September 25, 2026); Pfizer (August 2026); Moderna (updated October 3, 2026); Boston Scientific (November 2026); Recursion (November 2026); Sanofi (November 2026).
1.4
Which role
IAM analyst, engineer, PAM specialist or architect: which one you need
"IAM engineer" covers several quite different jobs, so it helps to decide which one you need before the search starts.
| Role | The work | Typical US base |
|---|---|---|
| IAM analyst or administrator | Access requests, account changes and running access review campaigns | $78,000 to $110,000 |
| IAM engineer (mid-level) | Builds connectors, workflows and integrations on one platform | $115,000 to $155,000 |
| Senior IAM engineer | Owns the identity stack and answers to the auditors | $150,000 to $200,000 |
| Privileged access (PAM) engineer, senior | Locks down administrator and service accounts, usually on CyberArk | $165,000 to $210,000 |
| Identity architect | Sets the target design across every application in the company | $185,000 to $245,000 |
KORE1's August 2026 guide says privileged access roles pay $10,000 to $25,000 more than general IAM at the same level. Its reasons: the candidate pool is small, and a mistake exposes the whole environment. FortHire's count of 106 identity jobs with published salaries in October 2026 put the median range at $164,382 to $221,550. The pharma ads above sit in similar bands, with Genentech's principal role reaching $263,500.
Sources: KORE1, IAM Engineer Salary Guide 2026 (August 2026); FortHire, Identity & Access Management salaries (October 27, 2026).
1.5
The hard part
Why IAM engineers with GxP experience are rare
The identity market is already tight. KORE1 describes supply as "tight" for governance engineers, "worse for Saviynt", and "very tight" for privileged access. It also notes that people almost never enter identity through a computer science degree. They arrive sideways, from the help desk or systems administration.
Pharma narrows the pool again. An engineer from a bank may have built an excellent SailPoint deployment and never worked on a validated system. There, a change to the role model needs a documented assessment, and access decisions may have to be shown to an inspector. A quality or validation specialist can quote Part 11 from memory without ever having written a connector. Both CVs can say "IAM", "SOX" and "regulated environment".
The lab adds a problem that office IT rarely meets. Some instruments, from chromatography systems to balances and pH meters, run on stand-alone computers. FDA has asked firms with findings to bring such equipment into the network with individual logins. Two of the three warning letters above involved lab instruments. Bringing them under central identity control without stopping testing is specialist work, and a job title does not show whether someone has done it.
The difference between these candidates only becomes clear when someone who understands both identity engineering and GxP talks them through work they have actually done. Telling those candidates apart is the hard, specialist part of an identity search, and it is what Geeqers does before you see a single CV.
Sources: KORE1, IAM Engineer Salary Guide 2026 (August 2026); Uday Shetty, review of FDA warning letters on computerized systems, January 2024 to July 2026 (July 2026).
1.6
Hire or outsource
Permanent IAM hire or a managed identity service?
Some companies bring in an implementation partner to install a governance or PAM platform. That can work well for the project itself. The question is who owns the result once the project team leaves.
Identity is not a system you finish. People join, move and leave every week, and the draft Annex 11 expects access to be granted, changed and revoked "in a timely manner" as that happens. Applications are added, mergers bring new directories, and audits recur. Somebody inside the company has to understand the role model, defend it to auditors and inspectors, and decide what changes when the business changes. Biogen, Genentech and Pfizer are all advertising for in-house identity engineers and architects to do that kind of work.
If a partner does the build, our advice is to hire the permanent owner before the project ends, so they learn the design from the people who built it. Our guides to DevSecOps engineers and cloud engineers cover the teams IAM engineers work most closely with as systems move to the cloud.
1.7
Our approach
How Geeqers runs an IAM search
Identity is one of the cybersecurity specialisms listed on our employer page. We recruit IAM analysts, engineers, privileged access specialists and identity architects for pharma, biotech and medical-device companies, as permanent members of your own team.
Before anyone reaches you, one of us has talked them through the identity work they have actually delivered and the audits it went through. Your shortlist arrives within 7 business days, and each name comes with a short note on platform depth and on the regulated systems the person has worked with.
The commercial side stays simple. Nothing is payable until your new hire starts, and the fee is agreed in writing before we begin. If the person leaves within 90 days, we search again for the same role at no extra fee. When a search needs to stay quiet, for example because it would hint at an audit finding or a merger you have not announced, we run it confidentially.
To get started, tell us which identity platforms you run and whether the role will touch GxP systems such as lab or quality applications. It also helps to know if the job is building the platform or owning it day to day. Share your hiring brief to start the search.
1.8
FAQ
Frequently asked questions
Is IAM part of cybersecurity?
Yes. Identity and access management is one of the core areas of cybersecurity. It controls who can log in to which systems and what they can do once inside. In pharma it also supports data integrity, because regulators expect every action on a GxP system to be traceable to one named person.
What does an IAM engineer do?
An IAM engineer sets up and maintains the systems that grant, change and remove user access. That usually means identity governance tools such as SailPoint or Saviynt, sign-in and multi-factor authentication on Entra ID or Okta, and privileged access tools such as CyberArk. They also support the access reviews and evidence that auditors ask for.
Does FDA require access control on GxP systems?
Yes. 21 CFR Part 11 requires limiting system access to authorized individuals and using authority checks for signing and changing records. 21 CFR 211.68(b) adds that only authorized personnel may change production and control records. In 2026 FDA cited shared logins and excessive administrator rights in several warning letters.
What does the draft Annex 11 say about identity and access management?
The July 2025 draft gives IAM its own section. It treats shared accounts, apart from read-only ones, as a violation of data integrity. It also asks for multi-factor login when critical systems are reached remotely, regular access reviews, and no administrator rights for people doing GMP work. As of late September 2026 the final text had not been published.
How much does an IAM engineer cost in the US in 2026?
KORE1's August 2026 guide puts mid-level IAM engineers at $115,000 to $155,000 base and senior engineers at $150,000 to $200,000. Pharma ads from autumn 2026 ranged from $140,000 to $187,250 at Biogen to $114,900 to $263,500 for a principal role at Genentech.
Which IAM tools do pharma companies use?
The ads we reviewed name SailPoint and Saviynt for identity governance, CyberArk for privileged access, and Microsoft Entra ID, Active Directory and Okta for sign-in and directories. Biogen's ad also names ServiceNow as the front end for access requests.
How fast can Geeqers find an IAM engineer?
Our shortlist arrives within 7 business days of a complete brief. Nothing is payable until the person starts work, and if they leave within 90 days we replace them for the same role at no extra fee.
Image: "A Man in Lab Gown Working on the Lab Computer" via Pexels, used under the Pexels licence, cropped. Figures were checked against the sources linked above in November 2026.















